Canadian Clinical Research
May 20th celebrates International Clinical Trials Day, as a time to give thanks and support to all the exceptionally hard-working clinical research pros out there! Their work is like putting together a massive puzzle that maps out the terrain of public health and medicine. We set aside May 20th each year to tip our hats…
Read More
First round of Innovation to Implementation Supplement (I2IS) grants awarded to five promising research projects taking unique approaches to addressing cancer. Excerpt from the Press Release: August 11, 2022, TORONTO – Five Ontario-based research projects will take the next step toward advancing cancer care in the province thanks to funding from the Ontario Institute for…
Read More
Lucira Announces Health Canada Authorization of First and Only 99% Accurate At-Home Covid & Flu Test
Excerpt from the Press Release: EMERYVILLE, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) — Lucira Health, Inc. (Nasdaq: LHDX) (“Lucira Health,” “Lucira” or the “Company”), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, today announced that Health Canada has granted Authorization under Interim Order for the emergency…
Read More
Two-dose series takes one month to complete, with similar vaccine efficacy estimates against Omicron to those seen in adults Excerpt from the Press Release: CAMBRIDGE, MA / ACCESSWIRE / July 14, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Health Canada has approved the use of…
Read More
– Patent valid through 2038 – Phase IIb ALS trial expected to commence H1 2022 Excerpt from the Press Release: CAMBRIDGE, Mass., April 6, 2022 /PRNewswire/ — NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) (“NeuroSense”), a company developing treatments for severe neurodegenerative diseases, today announced the Canadian Intellectual Property Office has granted the Company a key patent titled “Compositions…
Read More
Senior leaders in science, government, and industry recruited for international “Manhattan Project for the Brain” Excerpt from the Press Release: DUBAI, United Arab Emirates & PALO ALTO, Calif. & MONTREAL–(BUSINESS WIRE)–Neurotechnology Powerhouse NeuroVigil (ranked “Top 10 most innovative companies in health care” by Washington Post and Fast Company) announced at the New Technology & Mental…
Read More
3D Vector ECG Collection Device Slated for FDA 510k Submission in the Fourth Quarter of 2022 Excerpt from the Press Release: SANTA CLARA, Calif.–(BUSINESS WIRE)–HeartBeam, Inc. (NASDAQ: BEAT), a developmental stage digital healthcare company with a proprietary ECG telemedicine technology for heart attack detection, today announced it has signed a professional services agreement (the “Agreement”) with…
Read More
Follows U.S. approval for relapsed or refractory marginal zone lymphoma in 2021 Third approved indication for BRUKINSA in Canada, following mantle cell lymphoma (MCL) and Waldenström’s macroglobulinemia (WM) Excerpt from the Press Release: MISSISSAUGA, Ontario & CAMBRIDGE, Mass. & BEIJING & BASEL, Switzerland–(BUSINESS WIRE)–BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company…
Read More
Excerpt from the Press Release: SUNNYVALE, Calif., March 01, 2022 (GLOBE NEWSWIRE) — BioCardia®, Inc. (Nasdaq: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that it has received a No Objection Letter from Health Canada, the country’s health services agency, allowing the CardiAMP® Heart Failure Trial to…
Read More
Dormant Vaccine Manufacturing site currently owned by an affiliate of Liminal BioSciences intended to bring new capabilities to Ocugen’s medicine portfolio of Canadian and U.S. companies COVAXIN™ (BBV152), if approved, to be the first product manufactured in new upgraded facility New facility includes potential for manufacturing for breakthrough gene therapies and serve as R&D hub…
Read More